keflin neutral inj 2gm/vial powder for solution
eli lilly canada inc - cephalothin sodium - powder for solution - 2g - cephalothin sodium 2g - first generation cephalosporins
keflin add-vantage inj 1gm/vial liquid
eli lilly canada inc - cephalothin (cephalothin sodium) - liquid - 1g - cephalothin (cephalothin sodium) 1g - first generation cephalosporins
keflin powder for suspension
opsonin pharma limited - cephalexin - powder for suspension - 125 mg/5 ml
keflin n 2 gm vial powder for injection
eli lilly and company - cephalothin sodium - powder for injection - 2 g
keflin 1 g injection
pharmacare limited û woodmead - injection - see ingredients - each vial contains cephalothin sodium 1,087 g
kexin 2/2;ml inj
cadex lab - amikacin - inj - 100/250;mg - 2/2;ml
kexin 2ml inj
cadex lab - amikacin - inj - 500mg - 2ml
repatha solution
amgen canada inc - evolocumab - solution - 140mg - evolocumab 140mg - proprotein convertase subtilisin kexin type 9 (pcsk9) inhibitors
repatha solution
amgen canada inc - evolocumab - solution - 120mg - evolocumab 120mg - proprotein convertase subtilisin kexin type 9 (pcsk9) inhibitors
mycophenolate mofetil injection, powder, lyophilized, for solution
meitheal pharmaceuticals inc. - mycophenolate mofetil (unii: 9242ecw6r0) (mycophenolic acid - unii:hu9dx48n0t) - mycophenolate mofetil is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogenic kidney [see clinical studies (14.1)], heart [see clinical studies (14.2)] or liver transplants [see clinical studies (14.3)] , in combination with other immunosuppressants. allergic reactions to mycophenolate mofetil have been observed; therefore, mycophenolate mofetil is contraindicated in patients with a hypersensitivity to mycophenolate mofetil (mmf), mycophenolic acid (mpa) or any component of the drug product. mycophenolate mofetil is contraindicated in patients who are allergic to polysorbate 80 (tween). pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to mycophenolate during pregnancy and those becoming pregnant within 6 weeks of discontinuing mycophenolate mofetil treatment. to report a pregnancy or obtain information about the registry, visit www.mycophenolaterems.com or call 1-800-617